Pub Date : 2016-10-25DOI: 10.1080/20742835.2016.1239356
S. Mdletshe, Harry Munkupa, K. Lishimpi
Background: The current standard of radical treatment for patients with cancer of the cervix is combination therapy in the form of radiotherapy with chemotherapy. Generally the same treatment protocol is applied to HIV-positive and HIV-negative patients. However, HIV-positive patients with invasive cervical cancer have not been evaluated in detail regarding treatment response, its toxicities and compliance. Methods: This prospective, quantitative comparative study was conducted to evaluate acute toxicity in radical combination therapy, in HIV-positive (on HAART) and HIV-negative patients for cervical cancer at the Cancer Diseases Hospital, Lusaka, Zambia. In total, 120 stage IB2–IIIB cervical cancer patients were serially recruited to have an equal number of participants in each arm. Participants received cisplatin-based radical chemo-radiation for five to six weeks and were assessed for acute reactions in four systems: genitourinary, haematopoietic, skin, and gastrointestinal. Toxicity was scored using the NCI CTC v2.0. Results: The results revealed that there was no significant difference with regard to major acute reactions between the two groups. Radical chemo-radiation is therefore well tolerated by HIV-positive patients. Conclusion: Radical chemo-radiation in conventional doses was safely tolerated by a well-selected cervical cancer HIV-positive group on HAART and could be considered suitable for similar patients.
{"title":"Acute toxicity in cervical cancer HIV-positive vs. HIV-negative patients treated by radical chemo-radiation in Zambia","authors":"S. Mdletshe, Harry Munkupa, K. Lishimpi","doi":"10.1080/20742835.2016.1239356","DOIUrl":"https://doi.org/10.1080/20742835.2016.1239356","url":null,"abstract":"Background: The current standard of radical treatment for patients with cancer of the cervix is combination therapy in the form of radiotherapy with chemotherapy. Generally the same treatment protocol is applied to HIV-positive and HIV-negative patients. However, HIV-positive patients with invasive cervical cancer have not been evaluated in detail regarding treatment response, its toxicities and compliance. Methods: This prospective, quantitative comparative study was conducted to evaluate acute toxicity in radical combination therapy, in HIV-positive (on HAART) and HIV-negative patients for cervical cancer at the Cancer Diseases Hospital, Lusaka, Zambia. In total, 120 stage IB2–IIIB cervical cancer patients were serially recruited to have an equal number of participants in each arm. Participants received cisplatin-based radical chemo-radiation for five to six weeks and were assessed for acute reactions in four systems: genitourinary, haematopoietic, skin, and gastrointestinal. Toxicity was scored using the NCI CTC v2.0. Results: The results revealed that there was no significant difference with regard to major acute reactions between the two groups. Radical chemo-radiation is therefore well tolerated by HIV-positive patients. Conclusion: Radical chemo-radiation in conventional doses was safely tolerated by a well-selected cervical cancer HIV-positive group on HAART and could be considered suitable for similar patients.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"37 - 41"},"PeriodicalIF":0.3,"publicationDate":"2016-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2016.1239356","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-08-01DOI: 10.1080/20742835.2016.1212968
D. Long, H. Friedrich-Nel, G. Joubert
Objective: To establish patient-centred guidelines to assist multidisciplinary members in providing quality care for cervical cancer patients receiving brachytherapy. Design: A qualitative research design. Main measures: This prospective research study was conducted from July 2012 to March 2014 and constituted five stages. Stage 1: 28 one-to-one semi-structured patient interviews were conducted, stage 2: development of the proposed guidelines, stage 3: two focus group reviews of the proposed guidelines, stage 4: refinement of these guidelines by review by national heads of brachytherapy units and stage 5: presentation of the final guidelines. Results: Four main themes with sub-themes were identified from the patient interviews. Patients’ perspectives of care were integrated into the development process of the proposed guidelines. Guidelines were developed to address the practice setting and define the collective and exclusive roles and responsibilities of the radiation oncologists, radiation therapists and oncology nurses. Content validity, clarity and applicability of the guidelines were confirmed. Conclusion: Guidelines were established integrating the patient experience into the development process. They provide a framework that clearly defines the roles and responsibilities of each member of the multidisciplinary team. Members are encouraged to implement the guidelines to ensure that quality patient-centred care is delivered, rendering patient satisfaction.
{"title":"Brachytherapy for cervical cancer: guidelines to facilitate patient-centred care in a multidisciplinary environment","authors":"D. Long, H. Friedrich-Nel, G. Joubert","doi":"10.1080/20742835.2016.1212968","DOIUrl":"https://doi.org/10.1080/20742835.2016.1212968","url":null,"abstract":"Objective: To establish patient-centred guidelines to assist multidisciplinary members in providing quality care for cervical cancer patients receiving brachytherapy. Design: A qualitative research design. Main measures: This prospective research study was conducted from July 2012 to March 2014 and constituted five stages. Stage 1: 28 one-to-one semi-structured patient interviews were conducted, stage 2: development of the proposed guidelines, stage 3: two focus group reviews of the proposed guidelines, stage 4: refinement of these guidelines by review by national heads of brachytherapy units and stage 5: presentation of the final guidelines. Results: Four main themes with sub-themes were identified from the patient interviews. Patients’ perspectives of care were integrated into the development process of the proposed guidelines. Guidelines were developed to address the practice setting and define the collective and exclusive roles and responsibilities of the radiation oncologists, radiation therapists and oncology nurses. Content validity, clarity and applicability of the guidelines were confirmed. Conclusion: Guidelines were established integrating the patient experience into the development process. They provide a framework that clearly defines the roles and responsibilities of each member of the multidisciplinary team. Members are encouraged to implement the guidelines to ensure that quality patient-centred care is delivered, rendering patient satisfaction.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"27 - 33"},"PeriodicalIF":0.3,"publicationDate":"2016-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2016.1212968","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-07DOI: 10.1080/20742835.2015.1115197
M. Ajani, A. Salami, Oluwatosin Awolude, A. Oluwasola, E. Akang
Background: It has been proposed that the overexpression of the human epidermal growth factor receptor 2 (HER2/neu proto-oncogene) could be a possible therapeutic target in epithelial ovarian cancer, as has been the case in breast carcinomas. However, there is lack of knowledge on the status of the gene in neoplasms which occur in black women. The objective of this study was to determine HER2/neu expression status in EOC in black women. Method: Ninety cases of EOC were evaluated for HER2/neu protein expression using immunohistochemistry. Results: HER-2/neu expression was observed in 33 of the 90 cases (37%), of which 15 EOC cases (17%) were weakly or moderately positive, and 18 (20%) strongly positive. A significant association was not found between HER-2/neu expression and age, International Federation of Gynecologists and Obstetrics (FIGO) stage, grading and histological subtypes (p-values of 0.463, 0.360, 0.975 and 0.168, respectively). However, there were more cases of advanced-stage disease (III/IV) with HER-2 expression than early-stage EOC (I/II). In this study, 21%, 36% and 42% of HER2/neu-positive tumours were grades 1, 2 and 3, respectively. A higher proportion of serous carcinomas (as opposed to mucinous carcinomas) was also observed to be HER2/neu positive. Conclusion: HER2/neu expression was observed to increase with advanced stages of cancer, and was more commonly seen in serous, rather than in mucinous, carcinomas.
{"title":"The expression status of human epidermal growth factor receptor 2 in epithelial ovarian cancer in Ibadan, Nigeria","authors":"M. Ajani, A. Salami, Oluwatosin Awolude, A. Oluwasola, E. Akang","doi":"10.1080/20742835.2015.1115197","DOIUrl":"https://doi.org/10.1080/20742835.2015.1115197","url":null,"abstract":"Background: It has been proposed that the overexpression of the human epidermal growth factor receptor 2 (HER2/neu proto-oncogene) could be a possible therapeutic target in epithelial ovarian cancer, as has been the case in breast carcinomas. However, there is lack of knowledge on the status of the gene in neoplasms which occur in black women. The objective of this study was to determine HER2/neu expression status in EOC in black women. Method: Ninety cases of EOC were evaluated for HER2/neu protein expression using immunohistochemistry. Results: HER-2/neu expression was observed in 33 of the 90 cases (37%), of which 15 EOC cases (17%) were weakly or moderately positive, and 18 (20%) strongly positive. A significant association was not found between HER-2/neu expression and age, International Federation of Gynecologists and Obstetrics (FIGO) stage, grading and histological subtypes (p-values of 0.463, 0.360, 0.975 and 0.168, respectively). However, there were more cases of advanced-stage disease (III/IV) with HER-2 expression than early-stage EOC (I/II). In this study, 21%, 36% and 42% of HER2/neu-positive tumours were grades 1, 2 and 3, respectively. A higher proportion of serous carcinomas (as opposed to mucinous carcinomas) was also observed to be HER2/neu positive. Conclusion: HER2/neu expression was observed to increase with advanced stages of cancer, and was more commonly seen in serous, rather than in mucinous, carcinomas.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"13 - 9"},"PeriodicalIF":0.3,"publicationDate":"2016-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2015.1115197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-07DOI: 10.1080/20742835.2016.1175152
R. Bonanthaya, K. Lakshmaiah, S. Babu, D. Lokanatha
Aims: To evaluate the clinical outcome and complications with two different palliative chemotherapy regimens in recurrent cervical carcinoma. Methods and materials: Forty (40) women with recurrent cervical squamous cell carcinoma were treated with palliative chemotherapy using paclitaxel plus cisplatin or single-agent docetaxel. Clinical outcome and toxicities were analysed. The parameters in two arms were compared using Student’s t-test and statistical analysis was done using R software. Results: At a median follow up of 1.35 years the clinical outcome was complete response/partial response in 50% and 60% and progressive disease in 20% and 10% of the patients with either paclitaxel/cisplatin or docetaxel, respectively, which was not statistically significant. Stable disease (SD) was 30% in both arms. Toxicity included nausea, seen in all the patients in both arms, and diarrhoea, seen in 90% and 70% of the patients in the two arms, respectively. Grade II to III neutropenia was seen in 10% of patients with paclitaxel/cisplatin and none with docetaxel. Hypersensitivity was encountered in 40% and 30% in the two arms, respectively. Conclusion: There was no significant difference in clinical outcome and morbidity in patients with either paclitaxel/cisplatin or single-agent docetaxel. Further prospective clinical trials with larger study groups and longer follow-up are required to substantiate these claims.
{"title":"Palliative chemotherapy in recurrent carcinoma cervix: experience from a regional cancer centre in southern India","authors":"R. Bonanthaya, K. Lakshmaiah, S. Babu, D. Lokanatha","doi":"10.1080/20742835.2016.1175152","DOIUrl":"https://doi.org/10.1080/20742835.2016.1175152","url":null,"abstract":"Aims: To evaluate the clinical outcome and complications with two different palliative chemotherapy regimens in recurrent cervical carcinoma. Methods and materials: Forty (40) women with recurrent cervical squamous cell carcinoma were treated with palliative chemotherapy using paclitaxel plus cisplatin or single-agent docetaxel. Clinical outcome and toxicities were analysed. The parameters in two arms were compared using Student’s t-test and statistical analysis was done using R software. Results: At a median follow up of 1.35 years the clinical outcome was complete response/partial response in 50% and 60% and progressive disease in 20% and 10% of the patients with either paclitaxel/cisplatin or docetaxel, respectively, which was not statistically significant. Stable disease (SD) was 30% in both arms. Toxicity included nausea, seen in all the patients in both arms, and diarrhoea, seen in 90% and 70% of the patients in the two arms, respectively. Grade II to III neutropenia was seen in 10% of patients with paclitaxel/cisplatin and none with docetaxel. Hypersensitivity was encountered in 40% and 30% in the two arms, respectively. Conclusion: There was no significant difference in clinical outcome and morbidity in patients with either paclitaxel/cisplatin or single-agent docetaxel. Further prospective clinical trials with larger study groups and longer follow-up are required to substantiate these claims.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"14 - 17"},"PeriodicalIF":0.3,"publicationDate":"2016-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2016.1175152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-07DOI: 10.1080/20742835.2016.1180776
J. Butt, T. Wantenaar
Struma ovarii are a rare type of monodermal teratoma. Preoperative diagnosis of struma ovarii is difficult as the symptoms, clinical presentation and image on ultrasound are often similar to that of ovarian carcinoma. These patients, with mostly benign disease, often have more extensive surgery than necessary. We present the cases of four women who were diagnosed with struma ovarii postoperatively. They illustrate a range of symptoms and varied surgical approaches. The objective of this mini review is to raise awareness of the diagnosis of struma ovarii. The extensiveness of surgery, mostly in premenopausal women, can be reduced if there is a high suspicion of struma ovarii prior to surgery. An ovarian cyst with a large solid component may be suggestive of this diagnosis and also magnetic resonance imaging if possible, while serum thyroglobulin may aid in diagnosis. It is also prudent to test for hyperthyroidism if the diagnosis is suspected, to avoid thyroid crisis during surgery.
{"title":"The diagnosis and management of struma ovarii","authors":"J. Butt, T. Wantenaar","doi":"10.1080/20742835.2016.1180776","DOIUrl":"https://doi.org/10.1080/20742835.2016.1180776","url":null,"abstract":"Struma ovarii are a rare type of monodermal teratoma. Preoperative diagnosis of struma ovarii is difficult as the symptoms, clinical presentation and image on ultrasound are often similar to that of ovarian carcinoma. These patients, with mostly benign disease, often have more extensive surgery than necessary. We present the cases of four women who were diagnosed with struma ovarii postoperatively. They illustrate a range of symptoms and varied surgical approaches. The objective of this mini review is to raise awareness of the diagnosis of struma ovarii. The extensiveness of surgery, mostly in premenopausal women, can be reduced if there is a high suspicion of struma ovarii prior to surgery. An ovarian cyst with a large solid component may be suggestive of this diagnosis and also magnetic resonance imaging if possible, while serum thyroglobulin may aid in diagnosis. It is also prudent to test for hyperthyroidism if the diagnosis is suspected, to avoid thyroid crisis during surgery.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"24 - 26"},"PeriodicalIF":0.3,"publicationDate":"2016-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2016.1180776","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-07DOI: 10.1080/20742835.2015.1110419
J. Crasta, G. Ravikumar, Sharon Koorse, Premalatha Siddharta, E. Vallikad
Background: The objective of the study was to evaluate the expression of cell adhesion molecules [epithelial cadherin (E-cadherin)] and extracellular matrix protease [matrix metalloproteinase (MMP)-9] in preinvasive and invasive lesions of squamous neoplasia of the uterine cervix. Method: The study included 14 cases of cervical intraepithelial neoplasia (CIN) and 43 cases of squamous cell carcinoma (SCC). Immunohistochemistry (IHC) testing was performed for E-cadherin and MMP-9 using the polymer technique. The pathological prognostic parameters, like tumour grade, stage, lymphovascular space invasion and mitosis were compared with the expression of these markers. Results: The mean age of the patients with CIN was 40.1 years, and 50.9 years for those with SCC. Complete uniform membranous expression of E-caherin was demonstrated in the normal epithelium and most CIN (79%). MMP-9 was not expressed in the normal epithelium, whereas 43% of CIN (of which 67% were CIN grade III) were positive. Loss of membranous E-cadherin was shown in 88% of SCC, and MMP-9 with variable intensities expressed in 74%. A statistically significant association was established between the expression of these immune markers in preinvasive and invasive lesions, although there was no significant association with the prognostic parameters. In addition, the loss of E-cadherin was evident in patients with recurrence, while the expression of MMP-9 was demonstrated in 60%. Conclusion: The loss of membranous E-cadherin and the gain of cytoplasmic MMP-9 are markers of neoplastic transformation in squamous neoplasia of the uterine cervix. However, the expression of these immune markers in our study did not relate to the prognostic parameters, indicating the importance of these markers in early neoplastic transformation.
{"title":"Expression of adhesion molecule epithelial cadherin and matrix metalloproteinase-9 in squamous neoplasia of the uterine cervix","authors":"J. Crasta, G. Ravikumar, Sharon Koorse, Premalatha Siddharta, E. Vallikad","doi":"10.1080/20742835.2015.1110419","DOIUrl":"https://doi.org/10.1080/20742835.2015.1110419","url":null,"abstract":"Background: The objective of the study was to evaluate the expression of cell adhesion molecules [epithelial cadherin (E-cadherin)] and extracellular matrix protease [matrix metalloproteinase (MMP)-9] in preinvasive and invasive lesions of squamous neoplasia of the uterine cervix. Method: The study included 14 cases of cervical intraepithelial neoplasia (CIN) and 43 cases of squamous cell carcinoma (SCC). Immunohistochemistry (IHC) testing was performed for E-cadherin and MMP-9 using the polymer technique. The pathological prognostic parameters, like tumour grade, stage, lymphovascular space invasion and mitosis were compared with the expression of these markers. Results: The mean age of the patients with CIN was 40.1 years, and 50.9 years for those with SCC. Complete uniform membranous expression of E-caherin was demonstrated in the normal epithelium and most CIN (79%). MMP-9 was not expressed in the normal epithelium, whereas 43% of CIN (of which 67% were CIN grade III) were positive. Loss of membranous E-cadherin was shown in 88% of SCC, and MMP-9 with variable intensities expressed in 74%. A statistically significant association was established between the expression of these immune markers in preinvasive and invasive lesions, although there was no significant association with the prognostic parameters. In addition, the loss of E-cadherin was evident in patients with recurrence, while the expression of MMP-9 was demonstrated in 60%. Conclusion: The loss of membranous E-cadherin and the gain of cytoplasmic MMP-9 are markers of neoplastic transformation in squamous neoplasia of the uterine cervix. However, the expression of these immune markers in our study did not relate to the prognostic parameters, indicating the importance of these markers in early neoplastic transformation.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"4 - 8"},"PeriodicalIF":0.3,"publicationDate":"2016-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2015.1110419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-04-07DOI: 10.1080/20742835.2016.1175708
E. van Barneveld, D. Allen, R. Bekkers, P. Grant
Background: In early-stage endometrial cancer, lymphovascular space invasion (LVSI) is an independent predictor of relapse of disease and poorer survival. Nevertheless, adjuvant treatment for LVSI-positive patients is variable. Methods: Early-stage endometrial cancer patients with LVSI, treated in Melbourne between 2000 and 2010, were retrospectively reviewed. Outcomes of patients observed after hysterectomy were compared with those who had had adjuvant EBRT or VBT. Results: A total of 95 patients met the inclusion criteria. After surgery, 40 patients were observed, 48 patients received adjuvant EBRT and 7 adjuvant VBT. Nineteen patients developed recurrent disease (20.0%), of which 12.5% were in the observation group, 27.1% in the EBRT group and 14.3% in the VBT group (p-value 0.217). Fewer vaginal recurrences and more distant recurrences were found in both the RT groups (p-value 0.636 and 0.648 respectively). Multivariate analysis for overall survival (OS) and cancer-related survival (CRS) revealed a non-significant decrease of hazards in both the radiotherapy (RT) groups when compared with the observation group. Conclusions: In patients with LVSI, adjuvant RT was not shown to reduce recurrence rates or improve OS or CRS. Previous reports have suggested that LVSI may be as important as nodal status for the risk of distant recurrence, therefore the use of systemic therapy should be further investigated.
{"title":"Lymphovascular space invasion in early-stage endometrial cancer: adjuvant treatment and patterns of recurrence","authors":"E. van Barneveld, D. Allen, R. Bekkers, P. Grant","doi":"10.1080/20742835.2016.1175708","DOIUrl":"https://doi.org/10.1080/20742835.2016.1175708","url":null,"abstract":"Background: In early-stage endometrial cancer, lymphovascular space invasion (LVSI) is an independent predictor of relapse of disease and poorer survival. Nevertheless, adjuvant treatment for LVSI-positive patients is variable. Methods: Early-stage endometrial cancer patients with LVSI, treated in Melbourne between 2000 and 2010, were retrospectively reviewed. Outcomes of patients observed after hysterectomy were compared with those who had had adjuvant EBRT or VBT. Results: A total of 95 patients met the inclusion criteria. After surgery, 40 patients were observed, 48 patients received adjuvant EBRT and 7 adjuvant VBT. Nineteen patients developed recurrent disease (20.0%), of which 12.5% were in the observation group, 27.1% in the EBRT group and 14.3% in the VBT group (p-value 0.217). Fewer vaginal recurrences and more distant recurrences were found in both the RT groups (p-value 0.636 and 0.648 respectively). Multivariate analysis for overall survival (OS) and cancer-related survival (CRS) revealed a non-significant decrease of hazards in both the radiotherapy (RT) groups when compared with the observation group. Conclusions: In patients with LVSI, adjuvant RT was not shown to reduce recurrence rates or improve OS or CRS. Previous reports have suggested that LVSI may be as important as nodal status for the risk of distant recurrence, therefore the use of systemic therapy should be further investigated.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"18 - 23"},"PeriodicalIF":0.3,"publicationDate":"2016-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2016.1175708","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-20DOI: 10.1080/20742835.2015.1116186
P. Patil, B. Bharambe, Aditi H Mahure, M. Kurdukar, A. Patil, K. Deshpande
Extraovarian peritoneal serous papillary carcinoma is an uncommon malignant tumour characterised by peritoneal involvement with ascites, which is similar to ovarian serous papillary carcinoma histologically. Our case involved only the surface and superficial cortex of the ovaries, with peritoneal involvement, as described in the literature.
{"title":"A case report of primary psammomatous serous adenocarcinoma of the peritoneum","authors":"P. Patil, B. Bharambe, Aditi H Mahure, M. Kurdukar, A. Patil, K. Deshpande","doi":"10.1080/20742835.2015.1116186","DOIUrl":"https://doi.org/10.1080/20742835.2015.1116186","url":null,"abstract":"Extraovarian peritoneal serous papillary carcinoma is an uncommon malignant tumour characterised by peritoneal involvement with ascites, which is similar to ovarian serous papillary carcinoma histologically. Our case involved only the surface and superficial cortex of the ovaries, with peritoneal involvement, as described in the literature.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"8 1","pages":"1 - 3"},"PeriodicalIF":0.3,"publicationDate":"2016-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2015.1116186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-07-03DOI: 10.1080/20742835.2015.1081486
V. Antovska, M. Trajanova
Abstract Background: We carried out this study to evaluate the predictive value of an original risk of ovarian malignancy index (ROMI) devised by us. Method: Our ROMI was the simple sum of points from the three-stage gradation of serum cancer antigen 125 (CA-125), data from the patient’s familial and personal history and the ultrasound characteristics of the tumour (i.e. tumour size ≥ 6 cm, multilocularity, tumour with ≥ ¼ solid areas, dense and opalescent liquid, septum or papillary vegetation ≥ 3 mm), ascites, bilaterality, an unclear margin with respect to the surrounding tissue and thickness of the capsule ≥ 3 mm. Its originality lay in the three-stage CA-125 gradation, namely < 35 U/ml (1 point), 35-129 U/ml (3 points) and ≥ 130 U/ml (5 points). The study group comprised 274 patients divided into a group with benign tumours (BOT) (n = 205), and a group with malignant tumours (MOT) (n = 69). Both groups were subdivided into three subgroups of ROMI ≤ 11 (low risk), ROMI 12-14 (unclear risk) and ROMI ≥ 15 (high risk). Results: The cut-off ROMI of ≤ 11 showed high sensitivity, specificity and area under the curve (AUC) of 0.74, 0.93 and 0.83, respectively. The cut-off ROMI of ≤ 14 demonstrated extremely high specificity of 0.985, but lower sensitivity and AUC, of 0.57 and 0.78, respectively. Conclusion: Our newly devised ROMI and its cut-off of ≤ 11 is very effective in excluding, as well as confirming, ovarian cancer.
{"title":"An original risk of ovarian malignancy index and its predictive value in evaluating the nature of ovarian tumour","authors":"V. Antovska, M. Trajanova","doi":"10.1080/20742835.2015.1081486","DOIUrl":"https://doi.org/10.1080/20742835.2015.1081486","url":null,"abstract":"Abstract Background: We carried out this study to evaluate the predictive value of an original risk of ovarian malignancy index (ROMI) devised by us. Method: Our ROMI was the simple sum of points from the three-stage gradation of serum cancer antigen 125 (CA-125), data from the patient’s familial and personal history and the ultrasound characteristics of the tumour (i.e. tumour size ≥ 6 cm, multilocularity, tumour with ≥ ¼ solid areas, dense and opalescent liquid, septum or papillary vegetation ≥ 3 mm), ascites, bilaterality, an unclear margin with respect to the surrounding tissue and thickness of the capsule ≥ 3 mm. Its originality lay in the three-stage CA-125 gradation, namely < 35 U/ml (1 point), 35-129 U/ml (3 points) and ≥ 130 U/ml (5 points). The study group comprised 274 patients divided into a group with benign tumours (BOT) (n = 205), and a group with malignant tumours (MOT) (n = 69). Both groups were subdivided into three subgroups of ROMI ≤ 11 (low risk), ROMI 12-14 (unclear risk) and ROMI ≥ 15 (high risk). Results: The cut-off ROMI of ≤ 11 showed high sensitivity, specificity and area under the curve (AUC) of 0.74, 0.93 and 0.83, respectively. The cut-off ROMI of ≤ 14 demonstrated extremely high specificity of 0.985, but lower sensitivity and AUC, of 0.57 and 0.78, respectively. Conclusion: Our newly devised ROMI and its cut-off of ≤ 11 is very effective in excluding, as well as confirming, ovarian cancer.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"7 1","pages":"52 - 59"},"PeriodicalIF":0.3,"publicationDate":"2015-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2015.1081486","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60047304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-07-03DOI: 10.1080/20742835.2015.1030887
V. Bhatia, R. Taksande, A. Natekar, Z. Ali
According to the older literature, leiomyosarcoma (LMS) is the most common sarcoma of the uterus. But in 1993, the Gynecologic Oncology Group (GOG) found that the proportion of LMS of the uterus was only 16% of uterine sarcomas. 1,2 However, sarcomas comprise less than 1% of all cervical malignancies, 3 of which LMS is an extremely rare tumour, which follows an aggressive course. As per the world literature, only 22 cases 4 have been described. To our knowledge only two cases 4 have been reported in the Indian literature. We present a case study on a 40-year-old woman of Indian origin, who was diagnosed with cervical LMS.
{"title":"Cervical leiomyosarcoma: a rare entity","authors":"V. Bhatia, R. Taksande, A. Natekar, Z. Ali","doi":"10.1080/20742835.2015.1030887","DOIUrl":"https://doi.org/10.1080/20742835.2015.1030887","url":null,"abstract":"According to the older literature, leiomyosarcoma (LMS) is the most common sarcoma of the uterus. But in 1993, the Gynecologic Oncology Group (GOG) found that the proportion of LMS of the uterus was only 16% of uterine sarcomas. 1,2 However, sarcomas comprise less than 1% of all cervical malignancies, 3 of which LMS is an extremely rare tumour, which follows an aggressive course. As per the world literature, only 22 cases 4 have been described. To our knowledge only two cases 4 have been reported in the Indian literature. We present a case study on a 40-year-old woman of Indian origin, who was diagnosed with cervical LMS.","PeriodicalId":41638,"journal":{"name":"Southern African Journal of Gynaecological Oncology","volume":"7 1","pages":"64 - 66"},"PeriodicalIF":0.3,"publicationDate":"2015-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20742835.2015.1030887","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60046880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：